PXXL.F Stock Overview
Poxel S.A., a clinical-stage biopharmaceutical company, develops novel treatments for metabolic diseases, type 2 diabetes, and liver diseases.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Poxel S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €0.70 |
| 52 Week High | €0.83 |
| 52 Week Low | €0.55 |
| Beta | 1.57 |
| 1 Month Change | 28.44% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | -91.67% |
| Change since IPO | -91.86% |
Recent News & Updates
Recent updates
Shareholder Returns
| PXXL.F | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0% | -4.2% | -3.7% |
| 1Y | n/a | -2.0% | 20.5% |
Return vs Industry: Insufficient data to determine how PXXL.F performed against the US Biotechs industry.
Return vs Market: Insufficient data to determine how PXXL.F performed against the US Market.
Price Volatility
| PXXL.F volatility | |
|---|---|
| PXXL.F Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 11.5% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.4% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: PXXL.F has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine PXXL.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | 15 | Thomas Kuhn | www.poxelpharma.com |
Poxel S.A., a clinical-stage biopharmaceutical company, develops novel treatments for metabolic diseases, type 2 diabetes, and liver diseases. The company’s lead product is TWYMEEG (Imeglimin), an oral drug candidate that targets mitochondrial dysfunction and approved for the treatment of type 2 diabetes in Japan. It also develops PXL770, an adenosine monophosphate-activated protein kinase enzyme, which is in a Phase 2a clinical trial that treats chronic metabolic diseases, including diseases that affect the liver, such as non-alcoholic steatohepatitis (NASH); PXL065, an earlier stage programs that is in Phase 2 for the treatment of NASH focusing on chronic and rare metabolic indications.
Poxel S.A. Fundamentals Summary
| PXXL.F fundamental statistics | |
|---|---|
| Market cap | US$27.01m |
| Earnings (TTM) | -US$47.14m |
| Revenue (TTM) | US$1.65m |
15.4x
P/S Ratio-0.5x
P/E RatioIs PXXL.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PXXL.F income statement (TTM) | |
|---|---|
| Revenue | €1.55m |
| Cost of Revenue | €1.54m |
| Gross Profit | €2.00k |
| Other Expenses | €44.24m |
| Earnings | -€44.24m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
May 16, 2024
| Earnings per share (EPS) | -1.14 |
| Gross Margin | 0.13% |
| Net Profit Margin | -2,861.58% |
| Debt/Equity Ratio | -112.1% |
How did PXXL.F perform over the long term?
See historical performance and comparison